CA2318257A1 - Novel dosage form - Google Patents
Novel dosage form Download PDFInfo
- Publication number
- CA2318257A1 CA2318257A1 CA002318257A CA2318257A CA2318257A1 CA 2318257 A1 CA2318257 A1 CA 2318257A1 CA 002318257 A CA002318257 A CA 002318257A CA 2318257 A CA2318257 A CA 2318257A CA 2318257 A1 CA2318257 A1 CA 2318257A1
- Authority
- CA
- Canada
- Prior art keywords
- dose unit
- drug
- food
- pharmaceutical dose
- coating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
Landscapes
- Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention provides an orally administrable pharmaceutical dose unit of a size greater than 7 mm comprising a drug and an outer coating which is adapted to prevent release of said drug into the stomach or the small intestine when the pharmaceutical dose unit is in the presence of food. The present invention further provides an orally administrable pharmaceutical dose unit of a size greater than 7 mm which comprises a drug and an outer coating wherein the coating is made of a material that is soluble at pH values below 5.0 and is adapted to provide a separation of the pharmaceutical dose unit from co-administered food material. Preferably, the pharmaceutical dose unit is in the form of a coated tablet or capsule. Conveniently, the outer coating is a polymer. In addition, the invention relates to a method for separating an orally administrable pharmaceutical dose unit from co-administered food, and to the use of said pharmaceutical dose units in medicine.
Description
NOVEL DOS~~GE FORM
This invention relates to means fir oral delivery of a drug, aad specifically to means of avoiding changes in the rate of absorption of an s orally-delivered drug in the gastrointestinal tract due to the presence of co-administered food material.
The oral route of administration of drugs is a popular means of therapy.
Many drugs are well absorbed from the small intestines as well as the to large intestines, and such absorption is unaffected by the co-administration of foods. However, the absorption of a number of drugs is affected by the presence of food that is administered either with the dosage form or immediately after or before dosage foam administration. Such food effects have been well documented in the scientific literature, particularly by is Welling and colleagues (e.g. Welling 1977, J. Pharmacokinet. Biopharm.
5, 291-334; Welling 1989, Pharmac~. Ther. 43, 425-4.1; Williams et al.
1996, Eur. J. Drug Metab. Pharmacokin. 21, 201-11).
For some drugs the presence of food can increase the absorption of the 2o drug into the systemic circulation, wl0ereas for other drugs the food effect is associated with a reduction in absorption. Several different mechanisms are known to be responsible for such food effects. For example, food may increase the absorption of certain drugs due to improved dissolution of the drug, an effect which is promoted by a longer residence time of the 25 drug in the stomach, and by stimulation of bile which acts as a surface active agent thereby improving drug dissolution. Alternative mechanisms include the preferential transport of a drug into the lymphatic system in the presence of fats and fatty acid;>, and the inhibition or reduction of efflux systems, in particular p-glycoprotein, by specific food materials.
An example of this latter case is the enhanced absorption of drugs such as cyclosporin in the presence of grapefruit juice.
s The opposite effect, i. e. food causing a reduction in drug absorption, can also occur through a number of different mechanisms. For example, some drugs physically interact or complex with particular food types. This phenomenon is well known for the bisphosphonates and tetracyclines, which can interact with calcium present in dairy products. Drugs can also io be physically or chemically attached to food through various absorption processes. In addition, the drug and food (or digestion products thereof) may compete for the same absorption pathway. Indeed, some drugs are transported in the gastrointestinal tz~act, not by a process of passive diffusion, but by the exploitation o1.-' the pathways responsible for the is absorption of dietary peptides. Drugs in this class include the ~3-lactam antibiotics and several drugs useful in the treatment of cardiovascular diseases, such as captoprii. For the latter example, it has been clearly shown that if captopril is administered with foodstuffs high in protein, then the amount of drug reaching the; systemic circulation can be greatly 2o reduced. Another category of drugs known to be affected by foods is the peptidic thrombin inhibitors.
One simple strategy for avoiding food effects on drug absorption is to provide labelling for the patient that directs that the drug should not be 2s taken together with food, and preferably should be administered on a well-fasted stomach. While this may be possible in some clinical situations, it creates problems in certain patient groups and limits the utility of certain therapeutic products. From the standpoint of patient compliance, marketing and the avoidance of inappropriate levels of drugs, it would be advantageous if a drug could be administered with a food, or shortly before or after a meal, without the rate; of drug absorption being altered.
s The present invention seeks to provide a means of orally administering a drug which avoids or reduces the effects of co-administered food material on the rate of absorption of said drug.
In particular, the present invention provides an orally administrable io pharmaceutical dose unit of a size greater than 7 mm comprising a drug and an outer coating which is adapted to prevent release of said drug into the stomach or the small intestine whE;n the pharmaceutical dose unit is in the presence of food.
Zs The present invention further provides an orally administrable pharmaceutical dose unit of a size greater than 7 mm which comprises a drug and an outer coating wherein the coating is made of a material that is soluble at pH values below 5.0 and is adapted to provide a separation of the pharmaceutical dose unit from co-administered food material.
We have found that coating the pharmaceutical dose unit with a suitable material which is insoluble or only sparingly soluble at pH values above 5.0 can allow for retention of the intact dose unit in the upper regions of the gastrointestinal tract, thereby resulting in its separation from co-2s administered food material. Thus, die co-administered food is permitted to proceed along the gastrointestinal tract and so becomes located in the distal regions of the intestine, while the dose unit is retained in the stomach or proximal small intestines where it is subsequently broken down to release its contents. By this means, the system provides effective separation of the dose unit from co-administered food, thereby minimising any effect of such food material on the rate of absorption of important pharmacological agents.
Accordingly, a preferred embodiment of the present invention provides a pharmaceutical dose unit for oral delivery of a drug comprising said drug and an outer coating wherein the pharmaceutical dose unit has a size greater than 7 mm and wherein the coating is insoluble at pH values above to 5Ø
By "a pharmaceutical dose unit" we include the meaning of a pharmaceutical formulation or system containing a known amount of a drug. Preferably, the pharmaceutical <iose unit is in the form of a tablet or is capsule.
When the single dose unit is a tablet, it will have a core comprising the drug and typically one or more furttler ingredients of the type that are conventionally blended with drugs, ;such as an excipient, and an outer 2o coating or Iayer which surrounds the core and comprises a material which prevents release or any substantial release of the drug when the dose unit is in the presence of food, e.g. a material which is insoluble at pH values above 5Ø
25 When the single dose unit is a capsule, it will have a casing which encloses a compartment containing the drug and typically one or more further ingredients of the type that am conventionally blended with drugs, such as an excipient, and a barrier coating or layer on the outer surface of 4~
the casing which comprises a material which prevents release or any substantial release of the drug when the dose unit is in the presence of food, e.g. a material which is insoluble at pH values above 5Ø
When the drug is filled into a capsule, any of the capsules which have been fabricated to deliver medicaments to the human body may be employed. Suitable capsules include Those made of hard gelatin, starch or hydroxypropyimethyl cellulose.
to Starch capsules, e.g. as described i;a the United States Pharmacopoeia (USP), are preferred since these offer advantages in coating, i. e. in the storage and stability of the coating layer (PCT/GB95/01458).
By "starch capsules" we include capsules made from starch as well as ~s capsules made from modified starches or starch derivatives. By the term "derivatives" we particularly mean esters and ethers of the parent compound that can be unfunctionali,~ed or functionalised to contain, for example, ionic groupings.
2o Suitable starch derivatives include hydroxyethyl starch, hydroxypropyl starch, carboxymethyl starch, cationic starch, acetylated starch, phosphorylated starch, succinate derivatives of starch and grafted starches.
Such starch derivatives are well lc~iown and described in the art (for example Modified Starches: Properties and Uses, O. B. Wurzburg, CRC
25 Press Boca Raton (1986)).
The starches used should be of food or pharmaceutical quality.
The starch capsules can be made by an injection moulding process and typically comprise a body and a cap. 'The body is felled with the drug and the cap is then attached and sealed. Methods for making starch capsules are well known and are described, for example, in EP-A-118240, WO-s 901OS 161, EP-A-0304401, W O-92104408 and GB-2187703.
We have found that in human subjects it is possible to retain coated dose units intact within the stomach following their co-administration with a meal. The tablet or capsule only breaks up to release the drug contained to therein when the bulk of the food material within the stomach has emptied into the small intestine. The coating material selected for the invention is not an enteric material. Enteric coatings are defined as those materials that are insoluble in the acid conditions present in the human stomach but begin to dissolve at a higher pH that is typical of the small intestine is (i.e. pH 6.0 and above). Suitable coating materials for use in the present invention are those that dissolve ill the acid conditions of the fasted stomach (i. e. around pH 2.0), but are. insoluble or dissolve more slowly in the presence of food, where the pH of the stomach is increased to about pH 4.5 to 5.5 due to the slight buffering effect of food material. Since the 2o coating material does not dissolve, or dissolves slowly, in the fed stomach, the coated dose unit (tablet or capsule) retains its integrity, and does not break up and disperse its contents in the presence of food.
Conveniently, the coating material is a polymer, preferably a methacrylate 2s polymer. In a preferred embodiment of the present invention, the coating is Eudragit E100, a polymer of butylmethacrylate, (2-dimethyl aminoethyl} methacrylate, and methylmethacrylate in the weight ratio 1:2:1 (available from Rohm Pharma, Darmstadt, Germany), which dissolves when the pH falls below :5. Other polymers that would be suitable for use in the present invention include, but are not limited to, polyamino acids and polymeric materials, such as chitosan and poly-galactosamine, the solubility of which increase with a decrease in pH.
s Separation of an orally-administered pharmaceutical dose unit from co-administered food can be achieved for pharmaceutical dose units greater than about 7 mm in size. By "a size greater than 7 mm", we mean that the unit can be of any shape, preferably a conventional shape for a io pharmaceutical dose unit (such as a tablet or capsule), which has at least one linear dimension (i. e. length, width or depth) of greater than 7 mm, for example over 10 mm. Conveniently, the largest linear dimension is less than 20 mm. Units having a largest dimension of over 30 mm are generally unsuitable for oral delivery.
~s During the normal process of dige;>tion, food is mixed with acid and enzymes present in the stomach, and is subsequently broken down into small particles. These small particles of food are expelled through the pylorus into the small intestine. In contrast, a dose unit in the form of a 2o coated capsule or tablet greater than '~ mm in size is not removed from the stomach in the fed condition because the pylorus is in a constricted state.
The pylorus remains in a constricted state until the bulk of the food has been removed from the stomach sunk that the stomach again reaches a fasted state. The mechanisms involved in emptying food from the fed 2s stomach into the intestine and preventing the emptying of large, intact single units from the fed stomach have been well discussed in the literature. It is known, for example:, that an indigestible single unit will remain in the stomach until the food has been removed to the small intestine. In man, a physiological process known as the migrating myoelectric complex is known to control this process (Szurszewski 1969, Am. J. Physiol. 217, 1757-63). Hence, after the stomach is empty of food, there will be a period of approximately 1 - l lh hours before phase 3 s of the migrating myoelectric complex removes an intact coated tablet or capsule into the intestines. Thus, provided the drug is contained in a non-disintegrating single unit for a suitable period of time, the stomach will effectively permit separation of the encapsulated drug from the co-administered food.
to For many drugs that are vulnerable to food effects, it would be advantageous if the food were to be removed to the small intestines and for release of the drug to occur in the stomach. This is particularly the case for those drugs that exploit the d.i- and tri-peptide pathway, which is is known to be located in the upper ref;ions of the small intestine. In this case it would be most advantageous for the food to have passed the preferred absorption site in the intestines and for the capsule or tablet to break up in the stomach, thereby releasing the drug upstream from the preferred absorption site. We have found that this break up in the 2o stomach during the period between the emptying of the food and the onset of the clearance mechanism of the migrating myoelectric complex, can be achieved by the careful choice of size of the administered single unit and the coating polymer. We have particularly found that a polymer coating that is soluble within the pH range 2..i - 4.0 can provide the desired effect.
2s We believe that this effect is achieved because the polymer is poorly soluble in the stomach contents when, in food is present. However, as the food is removed from the stomach, the pH decreases and the polymer therefore begins to dissolve.
By using a coating thickness of a suitable size, it is possible to achieve the desired release of the drug in the stomach when the food is in the small intestine. Coating thickness may be determined by known methods, such s as by sectioning dose units and measuring the coat thickness by light or election microscopy. In practice, coat thickness may be determined by measuring dose unit weight gain during or following the coating process and calculating the coat thickness therefrom. A preferred thickness for the coating is between 20 and 200 ~cm, and more preferably between 40 and to 100 ~cm. As a further consequence of the pH buffering effect of food, in the event that the patient takes a second meal shortly after the first, then the capsule will not release its contents until the second meal has also been discharged into the small intestine. In effect, the tablet or capsule is able to discriminate as to whether it is in die presence of food in the stomach or 1s not.
A further aspect of the present invention provides a method for separating an orally administrable pharmaceutical dose unit from co-administered food comprising coating said pharmaceutical dose unit with a material that 2o is soluble at pH values below 5Ø
An additional aspect of the present invention provides pharmaceutical dose units for use in medicine. The present invention may be used to orally deliver a variety of drugs that suffer from food effects on administration.
2s These include, but are not limited to, the following examples;
amoxicillin, ampicillin, antipyrine, clodronate and other similar bisphosphonates, captopril, cephalexin, ketoconazoie, lysinopril, oxytetracycline, tetracycline, levodopa, methyldopa, methacycline, nafcillin, penicillamine, rifamycin, theophylline, peptidic thrombin inhibitors and Sampatrilat.
We believe the invention to be especially useful for the administration of s drugs that are negatively influenced by the presence of food; that is, the absorption is decreased in the presence of food. These include, but are not limited due, the ~i-lactam antibiotics, peptide-like drugs such as lysinopril and captopril, as well as the peptidic thrombin inhibitors.
Examples of the latter class of drug can be found in Bernatowicz et al.
to (I996), J. Med. Chem. 39, 4879.
Thus, the invention further provides the use of a drug and a coating material that is soluble at pH values below 5.0 in the preparation of an orally administrable pharmaceutical dose unit of a size greater than 7 mm 1s which is adapted to prevent release of the drug into the stomach or the small intestine when the pharmaceutical dose unit is in the presence of food.
The invention is now described, bw: not limited, with reference to the 2o following examples:
Example 1 - Preparation of coated starch capsules Starch capsules (size 0) were obtained from Capsugel (Switzerland) and 2s were filled with pharmaceutical exc:ipients together with a radiolabelled marker used to demonstrate capsule break up. The marker chosen was erbium oxide, that can be converted to a y-emitting material in a nuclear reactor. The contents of each capsule; were:
227 mg captopril 66.5 rng microcrystalline cellulose (Avicel Pfi 102) 5.5 mg erbium oxide s 5.0 mg magnesium stearate The preparation of the Eudragit E100 coating solution was as follows:
50 g Eudragit E100 to 25 g talc 20 ml water 730 ml isopropanol Initially, 50 g of Eudragit E100 was weighed into a plastic weighing boat.
is A solvent mixture comprising 730 ml of isopropanol and 20 ml of ultrapure water was prepared in a 1 litre measuring cylinder. Into a 1 litre glass bottle was transferred 600 rril of the isopropanol/water solution (130 ml of the ispropanol/water mixture was retained in the measuring cylinder). The Eudragit E100 was then slowly added to the 2o isopropanol/water solution while mixing vigorously with an overhead stirrer. Into a 250 ml beaker was weighed 25 g of talc, to which 80 ml of the retained isopropanollwater solution was added while mixing with a glass rod until a smooth paste was foamed. The talc paste was then added to the Eudragit solution, and the remaining isopropanol/water solution was 25 used to rinse the beaker before being added to the Eudragit/talc mixture.
The capsules were then coated with Eudragit E100 solution using an Aeromatic STREA-1 fluidised bed coater, as follows:
Into the chamber of the Aeromatic STREA-1 coater (standard column) (available from Niro Limited) were placed 55 drug-containing capsules and 450 g of placebo capsules. The Eudragit E100 coating solution was s applied to the starch capsules using tb~e following coating conditions, with minor modifications as appropriate:
Drying temperature 250"C
Fan speed 6 to Atomisation pressure 1 ba.r Pump speed Start at 1, increase to 2 as run proceeds To determine the weight gain of the capsules at intervals throughout the coating process, the drug-containing capsules were weighed and the is amount of Eudragit E100 coating applied per capsule was calculated. This weight gain figure was then used to calculate the coat thickness on the capsule. When the capsules had gained 65 mglcapsule in weight, the coating process was terminated andu the capsules were allowed to dry overnight.
Coating thickness can be calculated fi-om the weight gain as follows:
(i) The surface area of the capsule was calculated according to the equation:
2s Surface area (cm2) _ ~ x diameter (cm) x length (cm) For capsules of size 0, the surface area is 5 cm2.
:~2 (ii) Given that 1 mg of Eudragit E100 coating solution applied to a surface area of 1 cm2 yields a layer of 8 ~crn in thickness, a coat thickness was calculated using the weight gain of the capsule according to the s equation:
Coat thickness (gym) = weight gain ~mg]. x 8 surface area (cm2) to Hence, in the present example:
Coat thickness = (65/5) x 8 = 104 ~,m Dissolution testing:
is Three Eudragit E100-coated capsules were dissolution tested using the Van Kel dissolution apparatus (United States Pharmacopoeia dissolution method 2, using a basket) prior to neutron irradiation. A further five Eudragit E100 coated capsules were dissolution tested after neutron 2o irradiation. Eudragit E100-coated capsules were dissolution tested in pH 5 citric acid-disodium hydrogen phosphate buffer (McIlvaine's buffer).
Dissolution buffer samples (5 ml) were withdrawn at 15-minute intervals for a duration of 180 minutes. Each. dissolution sample was placed in a ml screw-top glass bottle for analysis of captopril content by HPLC, as 2s described in Kirschbaum and Perlma.n (1984) J. Pharm. Sci. 73, 686-7.
Results indicated that the capsules did not dissolve at pH 5.0 aad that neutron irradiation did not affect dhe solubility of the Eudragit E100 coating.
Example 2 - Preparation of coated gelatin capsules The procedure described in Example 1 for preparation of starch coated s capsules may also be used to coat capsules made from gelatin. Suitable gelatin capsules (size 0) include those obtained from Capsugel, Switzerland.
Example 3 - Preparation of a coated tablet io A tablet was prepared from microcrys~alline cellulose, containing the same radiolabel (erbium oxide) as described in Example 1, and 250 mg of captopril. The tablets were circular with a diameter of 15 mm, and were made by compression using the Manesty F3 machine with concave is punctures. The tablets were coated using a solution of polymer Eudragit E100, as described in Example 1.
An increase in weight of the tablets o~f 55 mg was used as an indication of suitable coating thickness. Tablet coating thickness can be calculated 2o using the same method as that described in Example 1, with the following equations being used to calculate surf~~ce area:
For circular (discoidal) tablets:
Surface area (cm2) _ (7c x diameter (cm) x height (cm)) 2s + (~ x radius2 (cm2)) For oblong tablets:
Surface area (cm2) = n x diameter (cm) x length (cm) Example 4 - In vivo evaluation In order to demonstrate the utility of the invention, a group of healthy s volunteers was selected and requested to fast overnight. On the study day, they were given radiolabelled, coated capsules (as described in Example 1) together with a meal containing a second radiolabel in the form of technetium-99m. The meal comprised scrambled eggs in which was incorporated technetium sulphur colloid, labelled with technetium-99m according to the procedure described by Knight et al. (1981), J. Nucl.
Med. 23, 21. Using this dual label approach, it was possible to distinguish between the position {and integrity) of the coated capsule and the position (and spreading) of the meal. This was achieved by placing the subject in front of a gamma camera, for example a General Electric is Maxi camera, field of view 40 cm. 'the break up of the capsules can be visualised on the camera and representative pictures obtained using a data capture method such as magnetic tape;. By this method it was possible to ascertain when the capsules broke up and whether they broke up in the stomach or in the small intestines. At: the time-point at which the capsules 2o broke up, it was also possible to ascE;rtain the location of the food within the gastrointestinal tract.
The results for nine subjects are shown in Table 1. It can be seen that in all but one case the capsules were retained in the stomach where they 2s broke up, releasing their contents. In contrast, the technetium-labelled food was found to be in the distal small intestine or in the colonic region.
Interestingly, in the one subject where the capsule was not retained in the stomach, it broke up in the upper rel;ions of the small intestines (probably close to the preferred absorption site for drugs exploiting the di- and tri-pedtide pathway) while the food had reached the colon or was located largely at the ileocecal junction. Thus, in all cases, it was demonstrated that effective separation of the drug delivery system from the co-s administered food was achieved.
O
~t7 ~
~ Q Q
C~ ..
i.d 1 1 H .~~. h ~, ~..,~. ~, o ~ v~ U
.-, b a d 'd O
O Ct~ :d ~.i O .d c U
,~~, ~ V1N d~ V'1O O~ V1 ~.O N N ~ M M N d' p M
~
_ H U
r,., ~ ~ a ~ '~
a H A
O ~ ~~; c~ o 0 o W o 0 0 ._ O a~ ~~~
~ ~ ~ N
y ~ ./
G
H
O U
O
.- .
N
c~a d' v0 0o cT
O
This invention relates to means fir oral delivery of a drug, aad specifically to means of avoiding changes in the rate of absorption of an s orally-delivered drug in the gastrointestinal tract due to the presence of co-administered food material.
The oral route of administration of drugs is a popular means of therapy.
Many drugs are well absorbed from the small intestines as well as the to large intestines, and such absorption is unaffected by the co-administration of foods. However, the absorption of a number of drugs is affected by the presence of food that is administered either with the dosage form or immediately after or before dosage foam administration. Such food effects have been well documented in the scientific literature, particularly by is Welling and colleagues (e.g. Welling 1977, J. Pharmacokinet. Biopharm.
5, 291-334; Welling 1989, Pharmac~. Ther. 43, 425-4.1; Williams et al.
1996, Eur. J. Drug Metab. Pharmacokin. 21, 201-11).
For some drugs the presence of food can increase the absorption of the 2o drug into the systemic circulation, wl0ereas for other drugs the food effect is associated with a reduction in absorption. Several different mechanisms are known to be responsible for such food effects. For example, food may increase the absorption of certain drugs due to improved dissolution of the drug, an effect which is promoted by a longer residence time of the 25 drug in the stomach, and by stimulation of bile which acts as a surface active agent thereby improving drug dissolution. Alternative mechanisms include the preferential transport of a drug into the lymphatic system in the presence of fats and fatty acid;>, and the inhibition or reduction of efflux systems, in particular p-glycoprotein, by specific food materials.
An example of this latter case is the enhanced absorption of drugs such as cyclosporin in the presence of grapefruit juice.
s The opposite effect, i. e. food causing a reduction in drug absorption, can also occur through a number of different mechanisms. For example, some drugs physically interact or complex with particular food types. This phenomenon is well known for the bisphosphonates and tetracyclines, which can interact with calcium present in dairy products. Drugs can also io be physically or chemically attached to food through various absorption processes. In addition, the drug and food (or digestion products thereof) may compete for the same absorption pathway. Indeed, some drugs are transported in the gastrointestinal tz~act, not by a process of passive diffusion, but by the exploitation o1.-' the pathways responsible for the is absorption of dietary peptides. Drugs in this class include the ~3-lactam antibiotics and several drugs useful in the treatment of cardiovascular diseases, such as captoprii. For the latter example, it has been clearly shown that if captopril is administered with foodstuffs high in protein, then the amount of drug reaching the; systemic circulation can be greatly 2o reduced. Another category of drugs known to be affected by foods is the peptidic thrombin inhibitors.
One simple strategy for avoiding food effects on drug absorption is to provide labelling for the patient that directs that the drug should not be 2s taken together with food, and preferably should be administered on a well-fasted stomach. While this may be possible in some clinical situations, it creates problems in certain patient groups and limits the utility of certain therapeutic products. From the standpoint of patient compliance, marketing and the avoidance of inappropriate levels of drugs, it would be advantageous if a drug could be administered with a food, or shortly before or after a meal, without the rate; of drug absorption being altered.
s The present invention seeks to provide a means of orally administering a drug which avoids or reduces the effects of co-administered food material on the rate of absorption of said drug.
In particular, the present invention provides an orally administrable io pharmaceutical dose unit of a size greater than 7 mm comprising a drug and an outer coating which is adapted to prevent release of said drug into the stomach or the small intestine whE;n the pharmaceutical dose unit is in the presence of food.
Zs The present invention further provides an orally administrable pharmaceutical dose unit of a size greater than 7 mm which comprises a drug and an outer coating wherein the coating is made of a material that is soluble at pH values below 5.0 and is adapted to provide a separation of the pharmaceutical dose unit from co-administered food material.
We have found that coating the pharmaceutical dose unit with a suitable material which is insoluble or only sparingly soluble at pH values above 5.0 can allow for retention of the intact dose unit in the upper regions of the gastrointestinal tract, thereby resulting in its separation from co-2s administered food material. Thus, die co-administered food is permitted to proceed along the gastrointestinal tract and so becomes located in the distal regions of the intestine, while the dose unit is retained in the stomach or proximal small intestines where it is subsequently broken down to release its contents. By this means, the system provides effective separation of the dose unit from co-administered food, thereby minimising any effect of such food material on the rate of absorption of important pharmacological agents.
Accordingly, a preferred embodiment of the present invention provides a pharmaceutical dose unit for oral delivery of a drug comprising said drug and an outer coating wherein the pharmaceutical dose unit has a size greater than 7 mm and wherein the coating is insoluble at pH values above to 5Ø
By "a pharmaceutical dose unit" we include the meaning of a pharmaceutical formulation or system containing a known amount of a drug. Preferably, the pharmaceutical <iose unit is in the form of a tablet or is capsule.
When the single dose unit is a tablet, it will have a core comprising the drug and typically one or more furttler ingredients of the type that are conventionally blended with drugs, ;such as an excipient, and an outer 2o coating or Iayer which surrounds the core and comprises a material which prevents release or any substantial release of the drug when the dose unit is in the presence of food, e.g. a material which is insoluble at pH values above 5Ø
25 When the single dose unit is a capsule, it will have a casing which encloses a compartment containing the drug and typically one or more further ingredients of the type that am conventionally blended with drugs, such as an excipient, and a barrier coating or layer on the outer surface of 4~
the casing which comprises a material which prevents release or any substantial release of the drug when the dose unit is in the presence of food, e.g. a material which is insoluble at pH values above 5Ø
When the drug is filled into a capsule, any of the capsules which have been fabricated to deliver medicaments to the human body may be employed. Suitable capsules include Those made of hard gelatin, starch or hydroxypropyimethyl cellulose.
to Starch capsules, e.g. as described i;a the United States Pharmacopoeia (USP), are preferred since these offer advantages in coating, i. e. in the storage and stability of the coating layer (PCT/GB95/01458).
By "starch capsules" we include capsules made from starch as well as ~s capsules made from modified starches or starch derivatives. By the term "derivatives" we particularly mean esters and ethers of the parent compound that can be unfunctionali,~ed or functionalised to contain, for example, ionic groupings.
2o Suitable starch derivatives include hydroxyethyl starch, hydroxypropyl starch, carboxymethyl starch, cationic starch, acetylated starch, phosphorylated starch, succinate derivatives of starch and grafted starches.
Such starch derivatives are well lc~iown and described in the art (for example Modified Starches: Properties and Uses, O. B. Wurzburg, CRC
25 Press Boca Raton (1986)).
The starches used should be of food or pharmaceutical quality.
The starch capsules can be made by an injection moulding process and typically comprise a body and a cap. 'The body is felled with the drug and the cap is then attached and sealed. Methods for making starch capsules are well known and are described, for example, in EP-A-118240, WO-s 901OS 161, EP-A-0304401, W O-92104408 and GB-2187703.
We have found that in human subjects it is possible to retain coated dose units intact within the stomach following their co-administration with a meal. The tablet or capsule only breaks up to release the drug contained to therein when the bulk of the food material within the stomach has emptied into the small intestine. The coating material selected for the invention is not an enteric material. Enteric coatings are defined as those materials that are insoluble in the acid conditions present in the human stomach but begin to dissolve at a higher pH that is typical of the small intestine is (i.e. pH 6.0 and above). Suitable coating materials for use in the present invention are those that dissolve ill the acid conditions of the fasted stomach (i. e. around pH 2.0), but are. insoluble or dissolve more slowly in the presence of food, where the pH of the stomach is increased to about pH 4.5 to 5.5 due to the slight buffering effect of food material. Since the 2o coating material does not dissolve, or dissolves slowly, in the fed stomach, the coated dose unit (tablet or capsule) retains its integrity, and does not break up and disperse its contents in the presence of food.
Conveniently, the coating material is a polymer, preferably a methacrylate 2s polymer. In a preferred embodiment of the present invention, the coating is Eudragit E100, a polymer of butylmethacrylate, (2-dimethyl aminoethyl} methacrylate, and methylmethacrylate in the weight ratio 1:2:1 (available from Rohm Pharma, Darmstadt, Germany), which dissolves when the pH falls below :5. Other polymers that would be suitable for use in the present invention include, but are not limited to, polyamino acids and polymeric materials, such as chitosan and poly-galactosamine, the solubility of which increase with a decrease in pH.
s Separation of an orally-administered pharmaceutical dose unit from co-administered food can be achieved for pharmaceutical dose units greater than about 7 mm in size. By "a size greater than 7 mm", we mean that the unit can be of any shape, preferably a conventional shape for a io pharmaceutical dose unit (such as a tablet or capsule), which has at least one linear dimension (i. e. length, width or depth) of greater than 7 mm, for example over 10 mm. Conveniently, the largest linear dimension is less than 20 mm. Units having a largest dimension of over 30 mm are generally unsuitable for oral delivery.
~s During the normal process of dige;>tion, food is mixed with acid and enzymes present in the stomach, and is subsequently broken down into small particles. These small particles of food are expelled through the pylorus into the small intestine. In contrast, a dose unit in the form of a 2o coated capsule or tablet greater than '~ mm in size is not removed from the stomach in the fed condition because the pylorus is in a constricted state.
The pylorus remains in a constricted state until the bulk of the food has been removed from the stomach sunk that the stomach again reaches a fasted state. The mechanisms involved in emptying food from the fed 2s stomach into the intestine and preventing the emptying of large, intact single units from the fed stomach have been well discussed in the literature. It is known, for example:, that an indigestible single unit will remain in the stomach until the food has been removed to the small intestine. In man, a physiological process known as the migrating myoelectric complex is known to control this process (Szurszewski 1969, Am. J. Physiol. 217, 1757-63). Hence, after the stomach is empty of food, there will be a period of approximately 1 - l lh hours before phase 3 s of the migrating myoelectric complex removes an intact coated tablet or capsule into the intestines. Thus, provided the drug is contained in a non-disintegrating single unit for a suitable period of time, the stomach will effectively permit separation of the encapsulated drug from the co-administered food.
to For many drugs that are vulnerable to food effects, it would be advantageous if the food were to be removed to the small intestines and for release of the drug to occur in the stomach. This is particularly the case for those drugs that exploit the d.i- and tri-peptide pathway, which is is known to be located in the upper ref;ions of the small intestine. In this case it would be most advantageous for the food to have passed the preferred absorption site in the intestines and for the capsule or tablet to break up in the stomach, thereby releasing the drug upstream from the preferred absorption site. We have found that this break up in the 2o stomach during the period between the emptying of the food and the onset of the clearance mechanism of the migrating myoelectric complex, can be achieved by the careful choice of size of the administered single unit and the coating polymer. We have particularly found that a polymer coating that is soluble within the pH range 2..i - 4.0 can provide the desired effect.
2s We believe that this effect is achieved because the polymer is poorly soluble in the stomach contents when, in food is present. However, as the food is removed from the stomach, the pH decreases and the polymer therefore begins to dissolve.
By using a coating thickness of a suitable size, it is possible to achieve the desired release of the drug in the stomach when the food is in the small intestine. Coating thickness may be determined by known methods, such s as by sectioning dose units and measuring the coat thickness by light or election microscopy. In practice, coat thickness may be determined by measuring dose unit weight gain during or following the coating process and calculating the coat thickness therefrom. A preferred thickness for the coating is between 20 and 200 ~cm, and more preferably between 40 and to 100 ~cm. As a further consequence of the pH buffering effect of food, in the event that the patient takes a second meal shortly after the first, then the capsule will not release its contents until the second meal has also been discharged into the small intestine. In effect, the tablet or capsule is able to discriminate as to whether it is in die presence of food in the stomach or 1s not.
A further aspect of the present invention provides a method for separating an orally administrable pharmaceutical dose unit from co-administered food comprising coating said pharmaceutical dose unit with a material that 2o is soluble at pH values below 5Ø
An additional aspect of the present invention provides pharmaceutical dose units for use in medicine. The present invention may be used to orally deliver a variety of drugs that suffer from food effects on administration.
2s These include, but are not limited to, the following examples;
amoxicillin, ampicillin, antipyrine, clodronate and other similar bisphosphonates, captopril, cephalexin, ketoconazoie, lysinopril, oxytetracycline, tetracycline, levodopa, methyldopa, methacycline, nafcillin, penicillamine, rifamycin, theophylline, peptidic thrombin inhibitors and Sampatrilat.
We believe the invention to be especially useful for the administration of s drugs that are negatively influenced by the presence of food; that is, the absorption is decreased in the presence of food. These include, but are not limited due, the ~i-lactam antibiotics, peptide-like drugs such as lysinopril and captopril, as well as the peptidic thrombin inhibitors.
Examples of the latter class of drug can be found in Bernatowicz et al.
to (I996), J. Med. Chem. 39, 4879.
Thus, the invention further provides the use of a drug and a coating material that is soluble at pH values below 5.0 in the preparation of an orally administrable pharmaceutical dose unit of a size greater than 7 mm 1s which is adapted to prevent release of the drug into the stomach or the small intestine when the pharmaceutical dose unit is in the presence of food.
The invention is now described, bw: not limited, with reference to the 2o following examples:
Example 1 - Preparation of coated starch capsules Starch capsules (size 0) were obtained from Capsugel (Switzerland) and 2s were filled with pharmaceutical exc:ipients together with a radiolabelled marker used to demonstrate capsule break up. The marker chosen was erbium oxide, that can be converted to a y-emitting material in a nuclear reactor. The contents of each capsule; were:
227 mg captopril 66.5 rng microcrystalline cellulose (Avicel Pfi 102) 5.5 mg erbium oxide s 5.0 mg magnesium stearate The preparation of the Eudragit E100 coating solution was as follows:
50 g Eudragit E100 to 25 g talc 20 ml water 730 ml isopropanol Initially, 50 g of Eudragit E100 was weighed into a plastic weighing boat.
is A solvent mixture comprising 730 ml of isopropanol and 20 ml of ultrapure water was prepared in a 1 litre measuring cylinder. Into a 1 litre glass bottle was transferred 600 rril of the isopropanol/water solution (130 ml of the ispropanol/water mixture was retained in the measuring cylinder). The Eudragit E100 was then slowly added to the 2o isopropanol/water solution while mixing vigorously with an overhead stirrer. Into a 250 ml beaker was weighed 25 g of talc, to which 80 ml of the retained isopropanollwater solution was added while mixing with a glass rod until a smooth paste was foamed. The talc paste was then added to the Eudragit solution, and the remaining isopropanol/water solution was 25 used to rinse the beaker before being added to the Eudragit/talc mixture.
The capsules were then coated with Eudragit E100 solution using an Aeromatic STREA-1 fluidised bed coater, as follows:
Into the chamber of the Aeromatic STREA-1 coater (standard column) (available from Niro Limited) were placed 55 drug-containing capsules and 450 g of placebo capsules. The Eudragit E100 coating solution was s applied to the starch capsules using tb~e following coating conditions, with minor modifications as appropriate:
Drying temperature 250"C
Fan speed 6 to Atomisation pressure 1 ba.r Pump speed Start at 1, increase to 2 as run proceeds To determine the weight gain of the capsules at intervals throughout the coating process, the drug-containing capsules were weighed and the is amount of Eudragit E100 coating applied per capsule was calculated. This weight gain figure was then used to calculate the coat thickness on the capsule. When the capsules had gained 65 mglcapsule in weight, the coating process was terminated andu the capsules were allowed to dry overnight.
Coating thickness can be calculated fi-om the weight gain as follows:
(i) The surface area of the capsule was calculated according to the equation:
2s Surface area (cm2) _ ~ x diameter (cm) x length (cm) For capsules of size 0, the surface area is 5 cm2.
:~2 (ii) Given that 1 mg of Eudragit E100 coating solution applied to a surface area of 1 cm2 yields a layer of 8 ~crn in thickness, a coat thickness was calculated using the weight gain of the capsule according to the s equation:
Coat thickness (gym) = weight gain ~mg]. x 8 surface area (cm2) to Hence, in the present example:
Coat thickness = (65/5) x 8 = 104 ~,m Dissolution testing:
is Three Eudragit E100-coated capsules were dissolution tested using the Van Kel dissolution apparatus (United States Pharmacopoeia dissolution method 2, using a basket) prior to neutron irradiation. A further five Eudragit E100 coated capsules were dissolution tested after neutron 2o irradiation. Eudragit E100-coated capsules were dissolution tested in pH 5 citric acid-disodium hydrogen phosphate buffer (McIlvaine's buffer).
Dissolution buffer samples (5 ml) were withdrawn at 15-minute intervals for a duration of 180 minutes. Each. dissolution sample was placed in a ml screw-top glass bottle for analysis of captopril content by HPLC, as 2s described in Kirschbaum and Perlma.n (1984) J. Pharm. Sci. 73, 686-7.
Results indicated that the capsules did not dissolve at pH 5.0 aad that neutron irradiation did not affect dhe solubility of the Eudragit E100 coating.
Example 2 - Preparation of coated gelatin capsules The procedure described in Example 1 for preparation of starch coated s capsules may also be used to coat capsules made from gelatin. Suitable gelatin capsules (size 0) include those obtained from Capsugel, Switzerland.
Example 3 - Preparation of a coated tablet io A tablet was prepared from microcrys~alline cellulose, containing the same radiolabel (erbium oxide) as described in Example 1, and 250 mg of captopril. The tablets were circular with a diameter of 15 mm, and were made by compression using the Manesty F3 machine with concave is punctures. The tablets were coated using a solution of polymer Eudragit E100, as described in Example 1.
An increase in weight of the tablets o~f 55 mg was used as an indication of suitable coating thickness. Tablet coating thickness can be calculated 2o using the same method as that described in Example 1, with the following equations being used to calculate surf~~ce area:
For circular (discoidal) tablets:
Surface area (cm2) _ (7c x diameter (cm) x height (cm)) 2s + (~ x radius2 (cm2)) For oblong tablets:
Surface area (cm2) = n x diameter (cm) x length (cm) Example 4 - In vivo evaluation In order to demonstrate the utility of the invention, a group of healthy s volunteers was selected and requested to fast overnight. On the study day, they were given radiolabelled, coated capsules (as described in Example 1) together with a meal containing a second radiolabel in the form of technetium-99m. The meal comprised scrambled eggs in which was incorporated technetium sulphur colloid, labelled with technetium-99m according to the procedure described by Knight et al. (1981), J. Nucl.
Med. 23, 21. Using this dual label approach, it was possible to distinguish between the position {and integrity) of the coated capsule and the position (and spreading) of the meal. This was achieved by placing the subject in front of a gamma camera, for example a General Electric is Maxi camera, field of view 40 cm. 'the break up of the capsules can be visualised on the camera and representative pictures obtained using a data capture method such as magnetic tape;. By this method it was possible to ascertain when the capsules broke up and whether they broke up in the stomach or in the small intestines. At: the time-point at which the capsules 2o broke up, it was also possible to ascE;rtain the location of the food within the gastrointestinal tract.
The results for nine subjects are shown in Table 1. It can be seen that in all but one case the capsules were retained in the stomach where they 2s broke up, releasing their contents. In contrast, the technetium-labelled food was found to be in the distal small intestine or in the colonic region.
Interestingly, in the one subject where the capsule was not retained in the stomach, it broke up in the upper rel;ions of the small intestines (probably close to the preferred absorption site for drugs exploiting the di- and tri-pedtide pathway) while the food had reached the colon or was located largely at the ileocecal junction. Thus, in all cases, it was demonstrated that effective separation of the drug delivery system from the co-s administered food was achieved.
O
~t7 ~
~ Q Q
C~ ..
i.d 1 1 H .~~. h ~, ~..,~. ~, o ~ v~ U
.-, b a d 'd O
O Ct~ :d ~.i O .d c U
,~~, ~ V1N d~ V'1O O~ V1 ~.O N N ~ M M N d' p M
~
_ H U
r,., ~ ~ a ~ '~
a H A
O ~ ~~; c~ o 0 o W o 0 0 ._ O a~ ~~~
~ ~ ~ N
y ~ ./
G
H
O U
O
.- .
N
c~a d' v0 0o cT
O
Claims
Claims:
1. An orally administrable pharmaceutical dose unit than 7 mm comprising a drug and an outer coating which is adapted to prevent release of said drug into the stomach or the small intestine when the pharmaceutical dose unit is in the presence of food.
2. An orally administrable pharmaceutical dose unit greater than 7 mm which comprises a drug and an outer coating wherein the coating is made of a material that is soluble at pH values below 5.0 and is adapted to provide a separation of the pharmaceutical dose unit from co-administered food material.
3. A pharmaceutical dose unit according to claim 1 or 2 in the form of a coated tablet or capsule.
4. A pharmaceutical dose unit according to claim 3, wherein the capsule is fabricated from gelatin, starch or hydroxypropylmethyl cellulose.
5. A pharmaceutical dose unit according to any one of claims 1 to 4, wherein the coating is soluble within the pH range 2.5 to 4Ø
6. A pharmaceutical dose unit according to any one of claims 1 to 5, wherein the coating is a polymer.
7. A pharmaceutical dose unit according to claim 6, wherein the polymer is Eudragit E100.
pharmaceutical dose unit with a material that is soluble at pH values below 5Ø
15. A pharmaceutical dose unit according to any one of claims 1 to 13 for use in medicine.
16. The use of a drug and a coating material that is soluble at pH values below 5.0 in the manufacture of an orally administrable pharmaceutical dose unit greater than 7 mm which is adapted to prevent release of the drug into the stomach or the small intestine when the pharmaceutical dose unit is in the presence of food.
1. An orally administrable pharmaceutical dose unit than 7 mm comprising a drug and an outer coating which is adapted to prevent release of said drug into the stomach or the small intestine when the pharmaceutical dose unit is in the presence of food.
2. An orally administrable pharmaceutical dose unit greater than 7 mm which comprises a drug and an outer coating wherein the coating is made of a material that is soluble at pH values below 5.0 and is adapted to provide a separation of the pharmaceutical dose unit from co-administered food material.
3. A pharmaceutical dose unit according to claim 1 or 2 in the form of a coated tablet or capsule.
4. A pharmaceutical dose unit according to claim 3, wherein the capsule is fabricated from gelatin, starch or hydroxypropylmethyl cellulose.
5. A pharmaceutical dose unit according to any one of claims 1 to 4, wherein the coating is soluble within the pH range 2.5 to 4Ø
6. A pharmaceutical dose unit according to any one of claims 1 to 5, wherein the coating is a polymer.
7. A pharmaceutical dose unit according to claim 6, wherein the polymer is Eudragit E100.
pharmaceutical dose unit with a material that is soluble at pH values below 5Ø
15. A pharmaceutical dose unit according to any one of claims 1 to 13 for use in medicine.
16. The use of a drug and a coating material that is soluble at pH values below 5.0 in the manufacture of an orally administrable pharmaceutical dose unit greater than 7 mm which is adapted to prevent release of the drug into the stomach or the small intestine when the pharmaceutical dose unit is in the presence of food.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9801363.4A GB9801363D0 (en) | 1998-01-22 | 1998-01-22 | Novel dosage form |
| GB9801363.4 | 1998-01-22 | ||
| PCT/GB1999/000193 WO1999037290A1 (en) | 1998-01-22 | 1999-01-20 | Novel dosage form |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2318257A1 true CA2318257A1 (en) | 1999-07-29 |
Family
ID=10825713
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002318257A Abandoned CA2318257A1 (en) | 1998-01-22 | 1999-01-20 | Novel dosage form |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP1059918A1 (en) |
| JP (1) | JP2002501016A (en) |
| AR (1) | AR014467A1 (en) |
| AU (1) | AU2176099A (en) |
| CA (1) | CA2318257A1 (en) |
| GB (1) | GB9801363D0 (en) |
| NO (1) | NO20003640L (en) |
| WO (1) | WO1999037290A1 (en) |
| ZA (1) | ZA99454B (en) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9910773D0 (en) * | 1999-05-11 | 1999-07-07 | West Pharm Serv Drug Res Ltd | Novel single unit coated dosage forms that can be used to minimise the effect of food on the absorption of drugs from the gastrointestinal tract |
| GB0102342D0 (en) * | 2001-01-30 | 2001-03-14 | Smithkline Beecham Plc | Pharmaceutical formulation |
| WO2006020009A1 (en) * | 2004-07-23 | 2006-02-23 | The Procter & Gamble Company | Solid oral dosage form of a bisphosphonate containing a chelating agent |
| US8836513B2 (en) | 2006-04-28 | 2014-09-16 | Proteus Digital Health, Inc. | Communication system incorporated in an ingestible product |
| SI1889198T1 (en) | 2005-04-28 | 2015-02-27 | Proteus Digital Health, Inc. | Pharma-informatics system |
| US8912908B2 (en) | 2005-04-28 | 2014-12-16 | Proteus Digital Health, Inc. | Communication system with remote activation |
| US9198608B2 (en) | 2005-04-28 | 2015-12-01 | Proteus Digital Health, Inc. | Communication system incorporated in a container |
| US8802183B2 (en) | 2005-04-28 | 2014-08-12 | Proteus Digital Health, Inc. | Communication system with enhanced partial power source and method of manufacturing same |
| KR20140018439A (en) | 2006-05-02 | 2014-02-12 | 프로테우스 디지털 헬스, 인코포레이티드 | Patient customized therapeutic regimens |
| JP5916277B2 (en) | 2006-10-25 | 2016-05-11 | プロテウス デジタル ヘルス， インコーポレイテッド | Ingestible control activation identifier |
| US8718193B2 (en) | 2006-11-20 | 2014-05-06 | Proteus Digital Health, Inc. | Active signal processing personal health signal receivers |
| US8858432B2 (en) | 2007-02-01 | 2014-10-14 | Proteus Digital Health, Inc. | Ingestible event marker systems |
| EP2111661B1 (en) | 2007-02-14 | 2017-04-12 | Proteus Digital Health, Inc. | In-body power source having high surface area electrode |
| WO2008112577A1 (en) | 2007-03-09 | 2008-09-18 | Proteus Biomedical, Inc. | In-body device having a multi-directional transmitter |
| WO2008112578A1 (en) | 2007-03-09 | 2008-09-18 | Proteus Biomedical, Inc. | In-body device having a deployable antenna |
| US8115618B2 (en) | 2007-05-24 | 2012-02-14 | Proteus Biomedical, Inc. | RFID antenna for in-body device |
| FI2192946T3 (en) | 2007-09-25 | 2022-11-30 | In-body device with virtual dipole signal amplification | |
| US20090135886A1 (en) | 2007-11-27 | 2009-05-28 | Proteus Biomedical, Inc. | Transbody communication systems employing communication channels |
| KR101661509B1 (en) | 2008-03-05 | 2016-09-30 | 프로테우스 디지털 헬스, 인코포레이티드 | Multi-mode communication ingestible event markers and systems, and methods of using the same |
| US20110009715A1 (en) | 2008-07-08 | 2011-01-13 | David O' Reilly | Ingestible event marker data framework |
| CA2734251A1 (en) | 2008-08-13 | 2010-02-18 | Proteus Biomedical, Inc. | Ingestible circuitry |
| SG172846A1 (en) | 2009-01-06 | 2011-08-29 | Proteus Biomedical Inc | Ingestion-related biofeedback and personalized medical therapy method and system |
| GB2480965B (en) | 2009-03-25 | 2014-10-08 | Proteus Digital Health Inc | Probablistic pharmacokinetic and pharmacodynamic modeling |
| SG10201810784SA (en) | 2009-04-28 | 2018-12-28 | Proteus Digital Health Inc | Highly Reliable Ingestible Event Markers And Methods For Using The Same |
| EP2432458A4 (en) | 2009-05-12 | 2014-02-12 | Proteus Digital Health Inc | Ingestible event markers comprising an ingestible component |
| TWI517050B (en) | 2009-11-04 | 2016-01-11 | 普羅托斯數位健康公司 | System for supply chain management |
| CN102905672B (en) * | 2010-04-07 | 2016-08-17 | 普罗秋斯数字健康公司 | Miniature ingestible device |
| TWI557672B (en) | 2010-05-19 | 2016-11-11 | 波提亞斯數位康健公司 | Computer system and computer-implemented method to track medication from manufacturer to a patient, apparatus and method for confirming delivery of medication to a patient, patient interface device |
| EP2642983A4 (en) | 2010-11-22 | 2014-03-12 | Proteus Digital Health Inc | Ingestible device with pharmaceutical product |
| US9756874B2 (en) | 2011-07-11 | 2017-09-12 | Proteus Digital Health, Inc. | Masticable ingestible product and communication system therefor |
| WO2015112603A1 (en) | 2014-01-21 | 2015-07-30 | Proteus Digital Health, Inc. | Masticable ingestible product and communication system therefor |
| BR112014001397A2 (en) | 2011-07-21 | 2017-02-21 | Proteus Biomedical Inc | device, system and method of mobile communication |
| US9235683B2 (en) | 2011-11-09 | 2016-01-12 | Proteus Digital Health, Inc. | Apparatus, system, and method for managing adherence to a regimen |
| AU2013293234B2 (en) | 2012-07-23 | 2017-08-31 | Otsuka Pharmaceutical Co., Ltd. | Techniques for manufacturing ingestible event markers comprising an ingestible component |
| MX340182B (en) | 2012-10-18 | 2016-06-28 | Proteus Digital Health Inc | Apparatus, system, and method to adaptively optimize power dissipation and broadcast power in a power source for a communication device. |
| TWI659994B (en) | 2013-01-29 | 2019-05-21 | 美商普羅托斯數位健康公司 | Highly-swellable polymeric films and compositions comprising the same |
| US11744481B2 (en) | 2013-03-15 | 2023-09-05 | Otsuka Pharmaceutical Co., Ltd. | System, apparatus and methods for data collection and assessing outcomes |
| JP5941240B2 (en) | 2013-03-15 | 2016-06-29 | プロテウス デジタル ヘルス， インコーポレイテッド | Metal detector device, system and method |
| US9796576B2 (en) | 2013-08-30 | 2017-10-24 | Proteus Digital Health, Inc. | Container with electronically controlled interlock |
| US10084880B2 (en) | 2013-11-04 | 2018-09-25 | Proteus Digital Health, Inc. | Social media networking based on physiologic information |
| US11051543B2 (en) | 2015-07-21 | 2021-07-06 | Otsuka Pharmaceutical Co. Ltd. | Alginate on adhesive bilayer laminate film |
| CN111772582A (en) | 2016-07-22 | 2020-10-16 | 普罗秋斯数字健康公司 | Electromagnetic sensing and detection of ingestible event markers |
| IL265827B2 (en) | 2016-10-26 | 2023-03-01 | Proteus Digital Health Inc | Methods for manufacturing capsules with ingestible event markers |
| US11458104B1 (en) * | 2018-06-21 | 2022-10-04 | Mission Pharmacal Company | Enteric coated tiopronin tablet |
| CN109453166B (en) * | 2018-10-16 | 2021-03-12 | 丹诺医药(苏州）有限公司 | Solid dispersion of rifamycin-quinolizinone coupled molecules and application thereof |
| CN110613697A (en) * | 2019-10-30 | 2019-12-27 | 长春迪瑞制药有限公司 | Cefalexin capsule and preparation method thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4786508A (en) * | 1986-05-30 | 1988-11-22 | Warner-Lambert Company | Coated dosage forms |
| FR2618331B1 (en) * | 1987-07-23 | 1991-10-04 | Synthelabo | PHARMACEUTICAL COMPOSITIONS USEFUL FOR THE TREATMENT OF UREMIA |
| AU618589B2 (en) * | 1988-04-05 | 1992-01-02 | Kyowa Hakko Kogyo Co. Ltd. | Oral compositions for ruminants |
-
1998
- 1998-01-22 GB GBGB9801363.4A patent/GB9801363D0/en not_active Ceased
-
1999
- 1999-01-20 AU AU21760/99A patent/AU2176099A/en not_active Abandoned
- 1999-01-20 EP EP99901758A patent/EP1059918A1/en not_active Withdrawn
- 1999-01-20 CA CA002318257A patent/CA2318257A1/en not_active Abandoned
- 1999-01-20 JP JP2000528272A patent/JP2002501016A/en active Pending
- 1999-01-20 WO PCT/GB1999/000193 patent/WO1999037290A1/en not_active Application Discontinuation
- 1999-01-21 ZA ZA9900454A patent/ZA99454B/en unknown
- 1999-01-22 AR ARP990100264A patent/AR014467A1/en unknown
-
2000
- 2000-07-14 NO NO20003640A patent/NO20003640L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| ZA99454B (en) | 2000-10-23 |
| AU2176099A (en) | 1999-08-09 |
| NO20003640L (en) | 2000-09-12 |
| EP1059918A1 (en) | 2000-12-20 |
| NO20003640D0 (en) | 2000-07-14 |
| GB9801363D0 (en) | 1998-03-18 |
| JP2002501016A (en) | 2002-01-15 |
| AR014467A1 (en) | 2001-02-28 |
| WO1999037290A1 (en) | 1999-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2318257A1 (en) | Novel dosage form | |
| AU707587B2 (en) | Composition for enhanced uptake of polar drugs from the colon | |
| FI118626B (en) | Drug composition for administration in colon | |
| EP0391518B1 (en) | Sustained-release pharmaceutical preparation | |
| KR100220322B1 (en) | Delayed release oral dosage forms for treatment of intestinal disorders | |
| US11744803B2 (en) | PH-controlled pulsatile delivery system, methods for preparation and use thereof | |
| US7445795B2 (en) | Delivery device, method of using and method of manufacturing | |
| CZ294641B6 (en) | Oral delayed immediate release formulation and method of preparation thereof | |
| Dobson et al. | The effect of oleic acid on the human ileal brake and its implications for small intestinal transit of tablet formulations | |
| JP2967492B2 (en) | Intestinal in-place release oral formulation | |
| Dobson et al. | Does the site of intestinal delivery of oleic acid alter the ileal brake response? | |
| WO2022245307A1 (en) | Composition of mesalazine enteric tablet formulation | |
| Nykänen | Development of multiple-unit oral formulations for colon-specific drug delivery using enteric polymers and organic acids as excipients | |
| More et al. | Duocapsule and alternative shell material to gelatin: Advancement in capsule formulation | |
| US20210113479A1 (en) | Dosage forms for delivery of medicines to the lower gastrointestinal tract | |
| GB2365336A (en) | Multiple capsules | |
| Reshma | Formulation and Evaluation of Olmesartan Medoxomil Pulsatile Drug Delivery System | |
| NZ565272A (en) | pH-controlled pulsatile delivery system, methods for preparation and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Dead |